Guillain-Barré Syndrome: Treatment, IVIG, and What Recovery Really Looks Like

Guillain-Barré syndrome (GBS) is an acute autoimmune attack on the peripheral nerves that can cause rapidly progressive weakness, numbness, and in severe cases, paralysis and breathing failure. Treatment in the acute phase relies on IVIG or plasma exchange, with most patients beginning to recover within weeks. However, the recovery timeline is often longer and more uneven than many patients are initially told, and understanding what to realistically expect makes the process less frightening.

What Is Guillain-Barré Syndrome?

One week you have a stomach bug or a respiratory infection. A nuisance, nothing more. Then your feet start tingling. Within days, the tingling becomes numbness. Then the weakness begins, creeping upward from your legs. For some people, it stops there. For others, it continues to climb until they cannot walk, cannot grip, cannot breathe on their own. This is the terrifying trajectory of Guillain-Barré syndrome.

GBS is an acute inflammatory condition in which the immune system, typically triggered by a preceding infection, turns against the body’s own peripheral nerves. The most common form, acute inflammatory demyelinating polyneuropathy (AIDP), damages the myelin sheath — the insulating coating around nerve fibers — disrupting the electrical signals that travel from the brain and spinal cord to the muscles and sensory organs.

GBS affects approximately 1 to 2 people per 100,000 each year, according to the National Institute of Neurological Disorders and Stroke. It can strike anyone at any age, though the risk increases slightly with age. About two-thirds of patients report a respiratory or gastrointestinal infection in the 1 to 6 weeks before symptoms begin. Campylobacter jejuni (a common cause of food poisoning) is the most frequently identified trigger, but influenza, Epstein-Barr virus, cytomegalovirus, and other infections can also set it off.

How GBS Begins and Progresses

GBS typically unfolds in three phases:

Phase 1: Progressive Weakness (Days to 4 Weeks)

Symptoms usually begin in the feet and legs and ascend upward. The hallmark is ascending, symmetric weakness. Both sides of the body are affected roughly equally. The progression can be gradual over weeks or alarmingly rapid over days.

Common symptoms during this phase:

• Tingling or “pins and needles” in the fingers and toes
• Weakness in the legs that makes walking difficult or impossible
• Weakness spreading to the arms, face, and trunk
• Pain — often described as deep, aching muscle pain or burning nerve pain. This is one of the most underappreciated aspects of GBS. The pain can be severe and may precede the weakness.
• Difficulty with balance and coordination
• Changes in blood pressure and heart rate (autonomic dysfunction)

Phase 2: Plateau (Days to Weeks)

Most patients reach their maximum weakness within 2 to 4 weeks (by definition, within 4 weeks; if weakness continues progressing beyond 8 weeks, the diagnosis shifts toward CIDP). During the plateau phase, symptoms stabilize but do not yet improve. This can be a psychologically difficult period — patients are at their weakest and may feel the recovery will never come.

Phase 3: Recovery (Weeks to Months to Years)

Recovery begins gradually. It generally follows the reverse of the onset pattern: muscles that were affected last tend to recover first. The speed and completeness of recovery vary enormously from person to person.

Acute Treatment: IVIG and Plasma Exchange

There are two proven treatments for the acute phase of GBS. Importantly, steroids — unlike in most other autoimmune conditions — do not work for GBS. Multiple trials have confirmed this, and steroids should not be used as treatment for GBS itself (though they may be needed for other reasons during hospitalization).

IVIG (Intravenous Immunoglobulin)

IVIG is the most commonly used acute treatment for GBS worldwide. The standard dose is 0.4 g/kg/day for 5 consecutive days (total dose 2 g/kg). It is typically started as soon as the diagnosis is confirmed and the patient has significant functional impairment (difficulty walking independently or worse).

How IVIG helps in GBS is not completely understood, but it appears to neutralize the harmful antibodies attacking the nerves, modulate the complement system, and reduce inflammation at the nerve level. For a detailed look at side effects and what to expect during infusion, see the IVIG side effects guide.

Plasma Exchange (PLEX)

Plasma exchange physically removes the antibodies attacking the nerves. A typical course involves 5 exchanges performed over approximately 10 days. PLEX was actually the first proven treatment for GBS and remains equally effective as IVIG.

IVIG vs. Plasma Exchange: How to Choose

Studies have shown that IVIG and PLEX are equally effective when started within the first 2 to 4 weeks of symptoms. Combining them does not provide additional benefit. The choice between them usually comes down to practical factors:

• IVIG is generally easier to administer (peripheral IV access rather than a central line), more widely available, and has fewer hemodynamic side effects. It is the more commonly chosen option.
• PLEX may be preferred in certain situations, such as when IVIG is contraindicated (severe IgA deficiency, recent thromboembolic events) or in settings where IVIG availability is limited.

A Realistic Recovery Timeline

This is perhaps the information GBS patients and families want most and find least readily available in straightforward terms. While every case is different, here is what the evidence and clinical experience suggest about the general pattern:

Rehabilitation: The Real Work

If IVIG or plasma exchange is the treatment that stops the attack, rehabilitation is the treatment that rebuilds the life. For many GBS patients, rehab is the hardest and most important part of the entire journey.

Inpatient Rehabilitation

Patients with significant weakness are typically transferred from the acute hospital to an inpatient rehabilitation facility, where they receive physical therapy (PT), occupational therapy (OT), and sometimes speech therapy multiple hours per day. The goals during this phase include:

• Preventing complications from immobility (blood clots, pressure sores, joint contractures)
• Rebuilding basic functional movements (sitting, standing, transfers)
• Managing pain, which can be intense and often requires a combination of neuropathic pain medications (gabapentin, pregabalin) and sometimes opioids in the acute phase

Outpatient Rehabilitation

After discharge from inpatient rehab, most patients continue with outpatient PT and OT for months. The focus shifts to:

• Improving walking endurance and balance
• Restoring hand function and fine motor skills
• Gradual return to activities of daily living (driving, cooking, work)
• Graduated exercise programs to rebuild cardiovascular fitness

The Fatigue Factor

GBS-related fatigue is one of the most common and persistent residual symptoms, reported by up to 80% of patients even years after the acute illness. It is not the same as normal tiredness. It is a deep, overwhelming exhaustion that descends without warning and is not fully relieved by rest. This fatigue is believed to result from the nervous system’s increased energy demands as it compensates for damaged nerve pathways. Acknowledging this to employers, family, and friends is important because it is invisible and often misunderstood.

When GBS Becomes CIDP

Guillain-Barré syndrome is, by definition, an acute and self-limiting condition. But in approximately 3-5% of patients initially diagnosed with GBS, the disease does not follow the expected one-time course. Instead, symptoms continue to worsen beyond 8 weeks, or the patient experiences relapses after initial improvement. When this happens, the diagnosis changes to chronic inflammatory demyelinating polyneuropathy, or CIDP.

The distinction matters enormously for treatment planning:

Long-Term Outcomes

The overall prognosis for GBS is cautiously optimistic, but the details matter:

• About 80% of patients are able to walk independently at 6 months, according to the GBS|CIDP Foundation International.
• About 60% recover full motor strength within one year, though many report persistent fatigue, pain, or sensory changes.
• About 5-10% have a prolonged or incomplete recovery, with lasting weakness or disability.
• About 3-5% die from complications, most commonly respiratory failure, cardiac arrhythmias, or pulmonary embolism during the acute phase. This underscores the importance of ICU-level monitoring early in the disease.
• Recurrence is uncommon but possible, occurring in about 2-5% of patients, usually years later.

Factors associated with a more difficult recovery include older age, rapid onset of severe weakness, need for mechanical ventilation, and evidence of axonal damage (as opposed to purely demyelinating disease) on nerve conduction studies.

The hardest part of GBS is not usually the acute phase, when everything is happening fast and the medical team is ever-present. The hardest part is often months later, when the hospital is a memory and the recovery is slow and lonely, and the world expects you to be “better” because you survived. Recovery is not the same as being the same.

For patients and families navigating GBS, connecting with the GBS|CIDP Foundation International can provide peer support, educational resources, and a community that understands the experience in a way that others often cannot. Understanding IVIG insurance coverage can also help if additional treatment is needed.